Filetype
The Translational Cancer Faster Forward doctoral/postdoctoral programmes (2018-2025). The CanFaster programme is supported by the European Union’s Marie Skłodowska-Curie COFUND programme (Horizon 2020 framework) based on the "Mobility across borders" philosophy. The CanFaster programme has attracted international PhD and Postdoc fellows (ER) with an interest in applied medical research in oncology
https://www.createhealth.lth.se/canfaster - 2025-06-19
The links below open on the respective publication website.In vivo dendritic cell reprogramming for cancer immunotherapy.Authors: Ascic, E., Catena, X., et al.Publication: Science 386, 6719Year: 2024Digital PCR quantification of ultrahigh ERBB2 copy number identifies poor breast cancer survival after trastuzumab.Authors: Meng, P., Dalal, H., Chen, Y., Brueffer, C., Gladchuk, S., Alcaide, M., ... &
https://www.createhealth.lth.se/canfaster/publications - 2025-06-19
Inducing anti-tumor immunity with in-situ direct reprograming of cancer cells to cDC1sNext generation immuno-oncological targets for cancer therapySubtype-dependent biomarkers for systemic therapy in bladder cancer
https://www.createhealth.lth.se/canfaster/ongoing-canfaster-postdoc-projects - 2025-06-19
Immunotherapy has transformed the cancer treatment landscape leading to long-term responses. However, these strategies are effective in a limited number of patients and often lose their efficacy as the tumor progresses. Insufficient antigen presentation mediated by MHC downregulation and exclusion of functional antigen-presenting cells (APCs) from the tumor microenvironment (TME) are critical evas
Immuno-oncological (I-O) treatment methods have revolutionized cancer therapy and tremendous clinical benefits are achieved in some cancer patients. However, today a limited number of I-O drug targets are used and only a fraction of all cancer patients has a therapeutic response. We need to further understand the immune system in cancer in order to develop novel treatment strategies and improve su
Cancer in the urinary bladder afflicts around 3000 persons per year in Sweden, most often older men and smokers. Despite being a quite common cancer type it is an understudied cancer type considering the burden to society and health outcomes [1].To patients with superficial cancer limited to the mucosa of the urinary bladder, the prognosis is good, but once the tumor has grown into the muscle-laye
Address Medicon Village - Building 406Sheelevägen 2 223 81 LundSweden Are you applying for a position? For general questions regarding the call, contact us at:canfaster-postdoc [at] immun [dot] lth [dot] se (canfaster-postdoc[at]immun[dot]lth[dot]se) DirectorSara Ek, Professorsara [dot] ek [at] immun [dot] lth [dot] se (sara[dot]ek[at]immun[dot]lth[dot]se)+46-46-222-3824 Research coordinatorJana H
https://www.createhealth.lth.se/canfaster/contact - 2025-06-19
Please wait... Address Medicon VillageBuilding 406Scheelevägen 2 223 81 LundSweden
https://www.createhealth.lth.se/contact - 2025-06-19
Our approach is translational - It starts from a specific need, identified by our clinical partners. We use novel technological approaches to find the relevant solutions, which can be implemented into the clinic with much shorter lead times. CREATE Health, inaugurated in 2006 with a focus on precision medicine, is a strategic centre for translational research focusing on the early diagnosis and pr
https://www.createhealth.lth.se/about - 2025-06-19
Focus AreasPsychological Resilience in Cancer, Bioinformatics and AIOngoing Collaborations and partnersCantargia, IMMUNOVIA, Paindrainer, Akuru PharmaSpin OutsWorking together is an integral part of CREATE Health’s DNA
https://www.createhealth.lth.se/research-and-innovation - 2025-06-19
CREATE Health has been a leader in developing novel therapeutic and diagnostic innovations, which have been further developed in a commercial setting in a start-up company. Immuno-OncologyImmuno-oncology has provided a number of very exciting clinical improvements, by focussing on how the immune system regulates tumor eradication. This has been achieved by the discovery and functional implementati
https://www.createhealth.lth.se/research-and-innovation/focus-areas - 2025-06-19
In 2025, CREATE Health Translational Cancer Center received a donation from the Mrs Berta Kamprad’s Cancer Foundation of 420 million SEK. This is the single largest donation to Lund University, since its founding in 1666. The funds are distributed over a five-year period and dedicated to translational cancer research within the L2CancerBridge program.Other previous and current funding for the CREA
https://www.createhealth.lth.se/about/funding - 2025-06-19
WCMM Fellow | Molecular Skeletal Biology Research focus Bone is a complex organ providing structural and mechanical support to our body, but also consisting in our principal hematopoietic centre. The formation of our bones is tightly and timely orchestrated, involving stages of cartilage, vasculature, bone and bone marrow establishment. Bourgine lab aims at compiling human-specific knowledge on ho
https://www.wcmm.lu.se/paul-bourgine - 2025-06-19
WCMM Fellow | Cell Reprogramming in Hematopoiesis and Immunity Our research The focus of our laboratory is to understand the molecular determinants underlying cell reprogramming and hematopoietic specification. In humans, the multiple differentiated cell states are normally stable and inherited through cell division. Under certain conditions, cell fate can, however, be modified or reversed. Cell r
https://www.wcmm.lu.se/filipe-pereira - 2025-06-19
2014 and 2015 marked the establishment of four Wallenberg Centres for Molecular Medicine at the universities of Gothenburg, Linköping, Lund and Umeå in collaboration with the respective health care regions. The centres represents an initial ten-year and more than 800 million SEK investment from The Knut and Alice Wallenberg Foundation (KAW), with a prolongation period for 2025-2028 with further fu
https://www.wcmm.lu.se/wallenberg-center-molecular-medicine-lund - 2025-06-19
Each year, trainees pair up to design a project that utilizies both of their skillsets. They then write a grant proposal based on training and feedback recieved in the research school. At the end, three winning proposals are awarded the Synergy grant with real funds to help them realize the common or individual research work.
https://www.wcmm.lu.se/wcmm-rs/wcmm-synergy-grants - 2025-06-19
The Wallenberg Center for Molecular Medicine (WCMM) Research School aims at training early career scientists (PhD students & Postdocs) in Molecular & Regenerative Medicine. It is designed to promote understanding of multidisciplinary research in regeneration, replacement and repair, and to provide training in cutting-edge translational research. Topics Interdisciplinary and translational lectures
https://www.wcmm.lu.se/wcmm-rs/overview-and-admission - 2025-06-19
VisionOur vision is to create novel breakthroughs in medicine through a strong collaborative approach between basic scientists and clinicians, a pioneering spirit and innovative leadership. MissionOur mission is to advance human health through cutting-edge research in molecular medicine. We uncover the molecular mechanisms underlying diseases and translate discoveries into transformative medical b
https://www.wcmm.lu.se/wallenberg-center-molecular-medicine-lund/vision-mission-statements - 2025-06-19
The WCMM Research School was a great opportunity for me to extend my local network at BMC, learn new state-of-the-art techniques/methods used in regenerative medicine, and get valuable feedback on my professional development from PIs currently in the phase of establishing their own labs. - John Stegmayr, PostDoc, LU A specific disease, although bounded to a single organ, rarely lacks secondary e
https://www.wcmm.lu.se/wcmm-rs/feedback-and-alumni - 2025-06-19
Iben LundgaardWCMM Research School CoordinatorGlia-Immune Interactions, senior lecturerPhone: +46 46 222 06 21Email: iben [dot] lundgaard [at] med [dot] lu [dot] se Joao DuarteWCMM Research School Coordinator Diabetes and Brain Function, senior lecturer Phone: +46 72 452 56 31 Email: joao [dot] duarte [at] med [dot] lu [dot] seKelley SwanbergWCMM Research School Assistant CoordinatorGlia-Immune In
https://www.wcmm.lu.se/wcmm-rs/research-school-coordinators - 2025-06-19
